

2025

ANNUAL CONFERENCE

CHINESE ANTIBODY SOCIETY

May 10th, 2025 Cambridge, MA

New Frontiers of Bispecific Antibodies, Antibody-Drug
Conjugates and Beyond

Welcome Letter from the Conference Organizers

Dear Colleagues,

On behalf of the Chinese Antibody Society (CAS) Board of Directors, we warmly welcome you to the CAS 2025 Annual Conference. This year's theme—"New Frontiers in Bispecific Antibodies, Antibody-Drug Conjugates, and Beyond"—highlights cutting-edge advancements and innovations shaping the future of antibody therapeutics.

Today, we are excited to bring together distinguished speakers from academia and industry to share insights into groundbreaking research, particularly in bispecific antibody engineering and antibody-drug conjugates (ADCs). We encourage you to participate actively in our interactive sessions, keynote presentations, and engaging panel discussions.

A central highlight of today's program is our interactive poster session. We congratulate the authors of approximately 20 top-selected abstracts, especially the three recipients of travel awards who will present their work in oral sessions. Please make sure to visit the poster area during coffee breaks and engage directly with emerging research and researchers.

Our official journal, Antibody Therapeutics, continues to advance significantly, recently being accepted into Clarivate's Emerging Sources Citation Index (ESCI) and achieving an impressive CiteScore of 8.7 in 2023. We encourage attendees to consider submitting their valuable research to Antibody Therapeutics.

Today's gathering and CAS's continued success are made possible through the generous contributions from our sponsors and partners. We express our sincere gratitude to them and encourage you to connect with their representatives in the exhibition hall.

We hope you find today's conference enriching and inspiring, offering ample opportunities to network, collaborate, and drive forward innovation in our field.

Thank you for joining us today, and we look forward to an exceptional conference.

Warmest regards,

Shouye Wang, PhD (Board of Directors)

Peng Lin, PhD (President)

Yufang Shao, PhD (President-Elect)



SPONSORS

TITLE SPONSORS



Dinner Sponsor



Lunch Sponsor



Sepax Technologies

Coffee Sponsor

PREMIUM SPONSORS



BEHIND THE SCENES

Board of Directors



Daotian Fu, PhD

**Chairman of Board
of Directors**

Dr. Daotian Fu has over 20 years of experience in biologics development, and currently is President of RemeGen Co., Ltd. Prior to joining RemeGen, Dr. Fu was Vice President & Managing Director of Livzon Pharmaceutical Group, a public company listed in both China and Hong Kong stock exchanges. While at Livzon, he was also General Manager of Livzon MabPharm, Inc., a clinical stage biologics development company. Prior to joining Livzon in May 2012, Daotian was Vice President at Genzyme, where he was responsible for the quality control and analytical development of all biologics at Genzyme. Dr. Fu received his BS from Shandong University in China, and his Ph.D. from Iowa State University. He also received post-doctoral training at University of Georgia.

Dr. Fu is currently the Chairman of the Board of Directors of Chinese Antibody Society.



Fubao Wang, PhD

Dr. Fubao Wang has been working in the pharmaceutical and biotech industry for more than twenty-five years at Merck, Sanofi, Sarepta, AskBio and currently at Prime Medicine as Senior Vice President, Head of Regulatory Affairs, focusing on Prime Editing technology-based product development.

Dr. Wang worked with gene editing, gene therapy, RNA therapeutics, Biologics including monoclonal antibody, and vaccine product development and directly contributed to BLA/NDA/MAA regulatory submissions and approvals of monoclonal antibody and RNA oligonucleotide products in major markets. He supported numerous INS/CTA clinical studies at all phases of Gene Therapy, RNA Therapeutics, Biologics, and vaccine development products. He also worked for the discovery and early development of preclinical candidates and life cycle management of approved commercial products.

Dr. Wang received his bachelor and master's degrees in Microbiology from Nankai University, China, Ph.D. degree in Molecular Biology from University of Heidelberg, Germany, and Postdoctoral training in Molecular Biology and Genetics at Stanford University, USA. Dr. Wang published peer-reviewed papers, reviews and book chapters and was a co-inventor of granted or filed patents.

Dr. Wang has been a member of the Board of Directors of Chinese Antibody Society since its inception and active in leading and supporting many Society's activities.



Jingsong Wang, MD, PhD

Dr. Jingsong Wang is the Founder, Chairman of the Board of Directors and CEO of Harbour BioMed (HBM, HKEX: 02142). Before establishing HBM, Dr. Wang served as the Head of China Research and Development Center and the Founding Head of Translational Medicine for Asia Pacific at Sanofi. Dr. Wang joined Sanofi from Bristol-Myers Squibb, where he served multiple roles with increasing responsibilities, including Director of Discovery Medicine and Clinical Pharmacology and Global Program Lead for multiple pre-clinical and clinical assets. Prior to BMS, Dr. Wang was at Wyeth (now part of Pfizer) where he served as Associate Director, and later as the Head for Translational Medicine in Inflammation and Rheumatology, Women's Health and Musculoskeletal Diseases.

Dr. Wang completed his Clinical Rheumatology Fellowship and subsequently was an Attending Rheumatologist and faculty member at Brigham and Women's Hospital and Harvard Medical School. Dr. Wang received his PhD in Molecular Pharmacology from China Pharmaceutical University and has also completed a Molecular Immunology Research Fellowship in the lab of Dr. Laurie Glimcher at the Harvard School of Public Health.

Dr. Wang currently is an Adjunct Assistant Professor of Medicine at the University of Pennsylvania. He has served on the Research Grant Review Committee, National Natural Science Foundation of China, and as a scientific grant reviewer for the Medical Research Council, National Institute for Health Research, National Health Service of the United Kingdom. Dr. Wang has published dozens of papers on various academic journals and is the author and co-author of numerous books in the field of translational medicine, inflammation and autoimmune diseases.



Mitchell Ho, PhD

Dr. Mitchell Ho is a Senior Investigator, Deputy Chief of the Laboratory of Molecular Biology, and Director of the Antibody Engineering Program at the National Cancer Institute (NCI), National Institutes of Health (NIH). He is the Chair of the Department of Biochemistry for the FAES Graduate School at the NIH. He also serves as the Editor-in-Chief for Antibody Therapeutics (Oxford University Press).

Dr. Ho's research has been focused on the development of new therapeutic paradigms for several difficult to treat cancers including liver cancer, rare cancers such as mesothelioma, and childhood cancers such as neuroblastoma. A major focus of Dr. Ho's research is on the structure and function of glypicans (e.g., GPC3, GPC2) and establishing them as new cancer-specific targets. This area of research ranges from investigation of the mechanisms by which glypicans regulate Wnt, Yap and other signaling pathways to the development of new antibody engineering technologies that lead to effective cancer therapeutics. In line with the antibody technology development, his lab has constructed shark and camel single-domain antibody phage libraries for therapeutic antibody discovery. Some of his laboratory research has direct clinical application. Clinical trials using the CAR-T cells created in his lab are ongoing for treating liver cancer and other cancers.

Dr. Ho received his Ph.D. from the University of Illinois at Urbana-Champaign. He completed a postdoctoral fellowship with Ira Pastan at the NIH/NCI. He was elected to the Board of Directors for the Antibody Society, the Board of Directors for the Chinese Antibody Society, and the Board of Directors for the Foundation for Advanced Education in the Sciences (FAES). He received Asian & Pacific Islander American Organization (APAIO) Scientific Achievement Award, NIH Deputy Director for Intramural Research (DDIR) Innovation Award, NIH Merit Award, NCI Director's Award and NCI Director's Innovation Award.



Shawn Shouye Wang, PhD

Dr. Shawn Shouye Wang was the founding president of Chinese Antibody Society, and is currently a Director of Board of Directors of the society. He has been a CMC Lead and a Senior Director at WuXi XDC since September, 2023. Before he joined WuXi XDC, he had worked for WuXi Biologics for nearly 7 years as a CMC Lead for many early stage integrated CMC (Chemistry, Manufacturing, and Control) projects for IND filing and late stage projects for BLA filing with US FDA, EU EMA, China NMPA, and/or other countries' regulatory agencies. He has worked on diverse modalities of biologics and vaccines including monoclonal antibodies, bispecific antibodies, antibody-drug conjugates (ADCs), Fc fusion proteins, and enzymes. In addition, he has been supporting WuXi Biologics' business expansion in the US, in particular the establishment of new sites in the US. He was Analytical Head of King of Prussia, PA site of WuXi Biologics in 2019. He coordinated/led the Biologics CMC Leadership training program of WuXi Biologics during 2017-2019, and also coordinated/led in 2022 series biologics CMC trainings for global sites in support of global expansion of WuXi Biologics. Prior to WuXi Biologics, he worked for Bristol-Meyers Squibb and Emergent Biosolutions. He obtained his PhD in protein chemistry from University of Science and Technology of China followed by postdoc trainings in Sweden and US.

Presidents of the Chinese Antibody Society

President of Chinese Antibody Society



Peng Lin, PhD, JD

Dr. Peng Lin will continue serving as President of the Chinese Antibody Society starting from 2024. Over the years, he has been involved in various aspects of the Society's operations, including serving on the Executive Committee and as Vice President from 2019 to 2023. Additionally, he held the position of General Manager from 2022 to 2023.

Dr. Lin is currently a principal at the leading international IP law firm Fish & Richardson. He graduated with high honors from Tsinghua University with a B.S. in Biology, received his Ph.D. in Human and Statistical Genetics from Washington University in St. Louis, and earned his J.D. cum laude from Harvard Law School. His practice emphasizes patent prosecution and counseling, opinion work, licensing, due diligence studies, and worldwide patent portfolio development and management. He has advised clients ranging from large publicly traded biopharmaceutical companies to emerging startup companies around the world for various IP needs.

President-Elect of Chinese Antibody Society



Yufang Shao, PhD

Dr. Yufang Shao is the founder of Bon Opus Biosciences LLC, a specialized contract research organization (CRO) focused on providing high-value biological reagents, from gene synthesis to protein and antibody production. Prior to founding Bon Opus, Dr. Shao served as a Principal Scientist at Roche in Nutley, NJ. She later established the U.S. operations of Novoprotein, where she led marketing and sales efforts from the ground up.

Dr. Shao earned her Ph.D. in Neurosciences from Stony Brook University and her B.S. from Fudan University. She completed her postdoctoral training at Memorial Sloan Kettering Cancer Center, where she subsequently held the position of Senior Scientist, working on high-throughput screening technologies.

Since 2016, Dr. Shao has also served as one of the founding Executive Committee members of the Chinese Antibody Society, contributing to the advancement of antibody research and collaboration within the scientific community.

VOLUNTEERS



Leyuan Bao	Hong Li	Xiaolu Qian	Zhinan Xia
Mi Cai	Lingxiao Li	Zhisong (Sean) Qiao	Xiao Xiao
Yi Cao	Nan Li	Wenwen Sha	Xiaoban Xin
Qianyu Chen	Shichang Li	Jianyu Shang	Zhuxuan (Kellen) Xu
Wenchun (Mark) Chen	Yan Li	Chun Shao	Lifei (Alex) Yang
Xi Chen	You Li	Chenxi Shen	Zhiyong Yang
Yuxin Chen	Yubin Li	Donghui (Stone) Shi	Chunxiao Yu
Zirong Chen	Haujiun Lian	Languang (Shining) Shi	Xin Yu
Ying Cong	Chen Liang	Sailing Shi	Hua Yuan
Mi (Tommy) Deng	Bo Liu	Wuliang Si	Hongyu Zhang
Linlin Dong	Cindy Liu	Wei (Julia) Su	Kaicong (Thom) Zhang
Tianci Dong	Cui Liu	Tao Tan	Lei Zhang
Yeping Dong	Jian Liu	Xianchun Tang	Lin Zhang
Yongli Dong	Ruihua (Louise) Liu	Yong Tang	Peiqing Zhang
Yue (Dina) Du	Weihan Liu	Weihong (Frank) Tao	Ran (Ellen) Zhang
Yitao (Tom) Feng	Xiaofeng Liu	Bo (Bob) Tian	Roushu Zhang
Zhiyun (Jean) Ge	Xiaoyang Liu	Zhidan (Daniel) Tu	Shujia (Sam) zhang
Xun Gui	Jing Lu	Baomei Wang	Xiangyang Zhang
Qifeng (Vincent) Han	Wei Lu	Chunjiao (John) Wang	Xu Zhang
Wei He	Zhaohua (Lucy) Lu	Kai Wang	Xuyao Zhang
Fagen Hu	Jie Ma	Meiyao Wang	Yanfeng Zhang
Miaohui Hu	Junyu Ma	Shouye (Shawn) Wang	Yong Zhang
Lei (Joy) Huang	Jia (Icy) Niu	Xin Wang	Zhuang Zhang
Xiaobin (Robin) Huang	Hong (Penny) Pan	Yuankai Wang	Hanchao Zhao
Guodong Hui	Ziwei (Jeffery) Pang	Xiang Wei	Frank Zhong
Haiqun (John) Jia	DongJun Peng	Huiwen Wu	Qingyao (Jessica) Zhou
Fuwei Jiang	Guoyuan Peng	Jingyuan (Jenny) Wu	Daocheng Zhu
Shikai Jin	Haiyong Peng	Siyuan (Melanie) Wu	Gaofeng (Golfer) Zhu
Fang Lao	Junpeng Qi	Yisheng Wu	

Executive Committee (EC) members:

Hongwei Han	Peng Lin	Yufang Shao	Cong Yao
Wei Jia	Guangbo Liu	Zheng Xiao	Ning Zhang

AGENDA

Registration (8:00 AM - 9:00 AM)

- 9:00 AM - 9:05 AM** **Opening Remarks**
Zhiqiang An, Vice President of Drug Discovery at the University of Texas Health Science Center
- 9:05 AM - 9:10 AM** **Announcements and Overview of Chinese Antibody Society**
Peng Lin, President, Chinese Antibody Society; Principal, Fish & Richardson

Morning session (9:10 AM - 10:10 PM)

- 9:10 AM - 9:40 AM** **Mining Antibody Biology for Novel Functionalities and Therapeutic Antibody Development**
Janine Schuurman, President, The Antibody Society
- 9:40 AM - 10:10 AM** **Unlocking the Potential of Bi-specific Myeloid Engagers (BiME) in Solid Tumor Immunotherapy**
Hongtao Lu, Co-Founder & CSO, Elpiscience Biopharmaceuticals

Coffee Break and Poster Session (10:10 AM - 11:10 AM)

Sponsored by



- 11:10 AM - 11:40 AM** **Next-Gen Immunotherapy: Engineering Multispecific Antibodies Against Tumor Resistance**
Ronnie Wei, Head of Biologics Discovery and Development, ModeX Therapeutics
- 11:40 AM - 12:10 PM** **Industry Trending of Antibody-Drug Conjugates CMC Development and GV20 ADC Development Strategy**
Jie Chen, CTO, GV20

Lunch Sponsor Presentation (12:10 PM - 12:30 PM)

- 12:10 PM - 12:30 PM** **Advancing Tumor Immunotherapy: Next-Gen MHC and Transmembrane Protein Platforms for High-Impact Discovery**
Manhee Suh, CTO, KactusBio

Lunch (12:30 PM - 1:30 PM)

Sponsored by



Poster Presentation & Best Poster Awards (1:30 PM - 2:05 PM)

1:30 PM - 2:05PM **Poster Presentation & Best Poster Awards**

Afternoon Session (2:05 PM - 5:45 PM)

2:05 PM - 2:35 PM **Transferrin Receptor Targeting Chimeras (TransTACs), a Heterobispecific Antibody Modality for Membrane Protein Degradation**

Xin Zhou, Assistant Professor, Harvard University

2:35 PM - 3:05 PM **End-to-End Discovery: Antibodies, Nanobodies, Biparatopics, and AI-Driven Insights**

André Teixeira, Institute for Protein Innovation

Coffee Break and Poster Session (3:05 PM - 3:50 PM)

Sponsored by



3:50 PM - 4:20 PM **Therapeutic mAb Discovery for Multi-pass Transmembrane Protein Targets**

Donghui Ma, CEO, DIMA Biotechnology

4:20 PM - 4:50 PM **MYTX-011: an Anti-cMET Antibody-Drug Conjugate Designed for Enhanced Payload Delivery to cMET Expressing Tumor Cells**

Nimish Gera, Scientific Co-Founder and VP, Mythic Therapeutics

4:50 PM - 5:35 PM **ADC Panel Discussion: Challenges and Opportunities of Next Generation ADCs for Cancers and Beyond**

Session chair and host: Rakesh Dixit, President & CEO, Regio Biosciences

Panelists: Bob Lutz, CSO, Iksuda Therapeutics

Benny Yang, CSO, Biocytogen

Nimish Gera, Scientific Co-Founder and VP, Mythic Therapeutics

5:35 PM - 5:45 PM **Closing Remarks**

Zhiqiang An, Vice President of Drug Discovery at the University of Texas Health Science Center

Social Hour (5:45 PM - 6:45 PM)

Dinner (Ticket Required) (6:45 PM - 8:45 PM)

Sponsored by



SPEAKERS & SESSION CHAIRS



Keynote Speaker

Janine Schuurman, PhD

President, The Antibody Society

Janine's career centers around the antibody molecule: as a biological source of inspiration and as a therapeutic modality.

Inspired to study biological mechanisms at the molecular level, she entered the antibody research domain during her PhD. After several post-doc positions, she decided to join Genmab's R&D team in 2000 as one of the first scientists. For over two decades, she passionately worked to develop innovative antibody therapeutics at Genmab, with her most recent position being Senior Vice President heading Genmab's Antibody Research and Technologies.

She is a co-inventor of many therapeutic antibodies including FDA-approved therapeutics RYBREVANT® (amivantamab) and (T)EPKINLY® (epcoritamab), and of the DuoBody®, HexaBody® and HexElect® technologies, which enable the generation of bispecific and effector-function enhanced antibodies. These technologies are being applied to antibody therapeutics discovery programs at leading pharmaceutical and biotechnology companies worldwide and have resulted in FDA-approved therapies such as RYBREVANT® (amivantamab), (T)EPKINLY® (epcoritamab), TECVAYLY® (teclistamab) and TALVEY® (talquetamab).

Dr. Schuurman has championed many successful academic and industry partnerships in antibody therapeutics and complementary research fields.

Dr. Schuurman joined The Antibody Society's Board of Directors in 2020 and currently serves as President of this international, non-profit trade association which represents individuals and organizations involved in antibody-related research and development.

Dr. Schuurman is frequently invited to serve as a speaker, as well as a chair, at scientific conferences around the world due to her vision, impactful scientific publication track record, and dynamic presentations.

She received her PhD in immunology from the University of Amsterdam.

Dr. Schuurman is currently an independent biotech consultant (Lust for Life Science B.V.) and collaborates with many organizations.



Hongtao Lu, PhD

Co-Founder & CSO, Elpiscience
Biopharmaceuticals

Dr. Hongtao Lu is the Co-founder and Chief Scientific Officer of Elpiscience Biopharma, a biotechnology company dedicated to developing innovative therapies in immunology and autoimmune diseases. A trained immunologist with over 25 years of industry experience, Dr. Lu has led drug discovery efforts across multiple therapeutic areas including autoimmune diseases, oncology, and neuroscience.

Before founding Elpiscience, Dr. Lu served as Co-founder and Executive Vice President of Scientific Research at Zai Lab, a NASDAQ-listed biopharmaceutical company. Prior to that, he was the founding head of the Neuroimmunology Discovery Performance Unit at GlaxoSmithKline, where he led the drug discovery and development for neuroinflammatory and neurodegenerative disorders.

Dr. Lu began his career at Berlex Biosciences and Bayer Schering Pharma, focusing on target identification and validation in autoimmune inflammatory diseases and oncology. He earned his Ph.D. in Regulatory Biology and conducted graduate research at the Cleveland Clinic Foundation, followed by a postdoctoral fellowship at Yale University School of Medicine under the mentorship of Dr. Richard Flavell.



Ronnie Wei, PhD, MBA

Head of Biologics Discovery
and Development, ModeX
Therapeutics

Dr. Ronnie R. Wei is a seasoned biopharmaceutical leader with nearly two decades of experience in biologics discovery and early-stage drug development, specializing in immune-oncology, immunology and infectious diseases. She has a proven track record of advancing transformative therapies from concept to clinical development, building high-performing multidisciplinary teams, and driving innovation in antibody-based therapeutics.

As the Head of Biologics Discovery and Development at ModeX Therapeutics, Dr. Wei played a pivotal role in establishing the company's strategic R&D direction, leading to its acquisition within 18 months. She spearheaded the development of proprietary multispecific antibody platforms and led efforts that resulted in multiple drug candidate nominations and IND-enabling studies, including immune-oncology programs advancing into clinical trials. Her leadership extended beyond science, playing a crucial role in business development, including fundraising and M&A activities.

Prior to ModeX, Dr. Wei held leadership positions at Sanofi, Dragonfly Therapeutics, and Genzyme, where she was instrumental in advancing innovative drug discovery platforms, and structuring high-impact collaborations. She contributed to the development of next-generation multispecific antibody platforms, including NK cell-engaging therapies and immune-modulating biologics. Her expertise also spans molecular engineering, protein sciences, digital biology, and machine learning applications in biologics.

Dr. Wei earned her PhD in Molecular, Cellular & Developmental Biology from Indiana University and an MBA from Boston College. Her groundbreaking contributions are reflected in an extensive portfolio of patents and high-impact publications, many of which focus on novel biologics for oncology and immune-oncology applications. Fluent in English and Mandarin, she is a thought leader and strategic decision-maker in the global biopharmaceutical industry, committed to advancing cutting-edge therapies for cancer and immune-related diseases.



ManHee Suh, PhD

CTO, Kactus Biosystems

Dr. ManHee Suh is an expert protein biochemist with structural biology training, specializing in biologics and vaccine development. He has a combined experience of over 25 years in protein engineering. Throughout his career, he has led teams across matrixed organizations to execute and deliver multiple technologies and biologics development projects.

Dr. ManHee Suh graduated with a Ph.D. from Bowling Green State University, where he focused on the molecular evolution of genes and proteins. During his post-doctoral studies at Cornell University, he investigated gene transcription regulation, with a particular focus on RNA polymerase complexes in the post-initiation steps, employing X-ray crystallography and biochemical analyses.

Dr. ManHee Suh is a co-founder and Chief Technology Officer (CTO) of Kactus Biosystems, a leading company in recombinant protein development for the biopharmaceutical industry. Prior to this role, he was Chief Scientist at BIOZAX and Principal Scientist/Scientific Consultant at Agave Biosystems. Dr. Suh also led as Principal Investigator on multiple United States Department of Defense (DoD) biological initiatives, notably DTRA (Defense Threat Reduction Agency), Air Force, and DARPA (Defense Advanced Research Projects Agency), pioneering novel biological technologies.



Jie Chen, MD

CTO, GV20 Therapeutics

Dr. Jie Chen currently serves as the Chief Technical Operations & Quality Officer of GV20 Therapeutics. She has 28 years of biopharmaceutical industry experience in leading biologics drug CMC development from discovery to IND/BLA filing and commercialization. Prior to GV20, she served as Senior Vice President/Site Head of US Manufacturing and Operations at WuXi Biologics where she was responsible for managing client CMC projects, leading US process development and manufacturing site design, buildup and operation. Previously, Dr. Chen also spent over 18 years in the biotech industry at Boston area including Dyax and Shire where she led Protein Sciences team, Process Sciences team, CMC team and managed CDMO for corresponding company biologics product development.

Dr. Chen received her M.D. from Medical School of Xian Jiao Tong University and practiced as an oncologist in China. She had her post-doctor fellow training at Univ. of Pennsylvania and holds a Master of Science in Physiology and Neurobiology from Rutgers University.



Xin Zhou, PhD

Assistant Professor, Harvard University

Xin Zhou is an Assistant Professor of Department of Biological Chemistry & Molecular Pharmacology at Harvard Medical School and Department of Cancer Biology at Dana-Farber Cancer Institute. She received a PhD in Bioengineering with Dr. Michael Lin at Stanford University and completed her postdoctoral training with Dr. James Wells at University of California, San Francisco. The Xin Zhou lab engineers proteins to control, measure, and rewire cell-surface signaling, aiming to construct precise spatiotemporal maps of cell signaling pathways and establish new therapeutic strategies for controlling cell function and fate. Xin's work has been recognized with awards such as the NIH Director's New Innovator Award, the NIH K99/R00 Pathway to Independence Award, the Damon Runyon Cancer Research Foundation-Dale F. Frey Award for Breakthrough Scientists, and the DFCI Accelerator Therapeutic LEAP Award.



Andre Teixeira, PhD

Senior Director and Head of Antibody Platform, Institute for Protein Innovation

André A R Teixeira, PhD, is the Senior Director of the Antibody Platform at the Institute for Protein Innovation (IPI), leading efforts in antibody discovery and protein engineering. With a background in pharmacy and drug discovery, he develops high-throughput, library-based approaches to engineer novel antibodies and study immune responses.

At IPI, Dr. Teixeira leads an end-to-end discovery platform, integrating antigen production, yeast display, next-generation sequencing, and lead production. His team runs 200 discovery campaigns annually with a high success rate, generating novel antibodies and data to support AI-driven antibody engineering.

Dr. Teixeira collaborates with pharma, biotech, and academia, contributing to multiple patents and publications. His work advances biologics and platform development.



Donghui Ma, PhD

CEO, DIMA Biotechnology

Dr. Donghui Ma got his PhD and Postdoc trainings from National University of Singapore and Johns Hopkins. He is the CEO and founder for DIMA Biotechnology LTD. Currently DIMA already collected more than 5000 functionally validated IgG sequences against 498 druggable targets. These sequences are all ready to evaluate and for quick out-license. Different from traditional CRO service business model, DIMA offers zero upfront payment program for these 5000+ off-the-shelf and pre-validated mAb molecules.



Nimish Gera, PhD

Scientific Co-Founder & Vice
President of Biologics, Mythic
Therapeutics

Nimish Gera is the Scientific Co-Founder and Vice President of Biologics at Mythic Therapeutics overseeing the Company's research pipeline of antibody-drug conjugates (ADCs). Nimish's broad experience in biotech and pharmaceuticals encompasses various modalities (monoclonal antibodies, bispecific antibodies, protein-fusions, and antibody-drug conjugates) and therapeutic areas (oncology, immuno-oncology, autoimmune, and rare disease). Prior to Mythic, Nimish served as a project leader and principal investigator at Alexion Pharmaceuticals, where he led and managed diverse cross-functional project teams to lead two bispecific antibody programs into development, including gefurulumab (currently in Phase III for generalized myasthenia gravis). Prior to Alexion, Nimish helped establish discovery sciences function at Oncobiologics (now Sonnet BioTherapeutics) and identified multiple lead candidates for the company's platform. He earned a PhD in chemical and biomolecular engineering with a minor in biotechnology at North Carolina State University. Nimish also serves as an Associate Editor of mAbs and has a successful track record of several peer-reviewed publications, patents and chairing national and international meetings on antibody discovery and engineering, developability and ADCs.



Rakesh Dixit, PhD, DABT

President & CEO, Regio
Biosciences

Rakesh Dixit is an accomplished executive, inventor, and scientist with over 35 years of success with top biotechnology and pharmaceutical companies, including Merck, Johnson & Johnson, and MedImmune - AstraZeneca. He is President and CSO of Regio Biosciences and Bionavigen Oncology, LLC. He is a Board Member of Regio Biosciences and a key member of multiple scientific advisory boards. Rakesh is also a chief adviser and consultant for over 20 companies worldwide. His biopharmaceutical peers selected Rakesh as one of the 100 Most Inspiring People in the Pharmaceutical Industry by PharmaVOICE in 2015. Rakesh received the Most Prestigious Award of Long-Standing Contribution to ADCs by World ADC (Hanson-Wade), 2020. From 2006 to 2019, Rakesh was a Global Vice President of the Biologics R&D at MedImmune - AstraZeneca. Rakesh has unique expertise in developing biologics (e.g., monoclonal antibodies, bispecific biologics, antibody-drug conjugates, fusion proteins, peptides, gene and cell therapies, etc.) and small-molecule biopharmaceuticals. His expertise includes discovery, early and late preclinical development, safety assessment, DMPK, and translational sciences. Dr. Dixit conducted extensive graduate and post-graduate training in Pharmacology/ Toxicology–Biochemistry with both Indian and USA Institutions (e.g., Case Western Reserve University, Medical College of Ohio, University of Nebraska) and is a Diplomate and Board Certified in Toxicology from the American Board of Toxicology, Inc. since 1992.



Bob Lutz, PhD

CSO, Iksuda Therapeutics

Bob Lutz has extensive experience in the development of antibody-based therapeutics. He has been providing advisory support to emerging biotech and pharma since 2015, serving in C-level roles for multiple clients. Prior to initiating his advisory practice, Bob held various R&D leadership roles over a 23-year span at ImmunoGen, Inc., including VP of Translational R&D. Bob served as research lead on Genentech's trastuzumab emtansine (Kadcyla®) program and as early-stage development lead on mirvetuximab soravtansine (Elahere®).

Bob earned his PhD in Biochemistry at Brandeis University and was a research and postdoctoral fellow at the Eleanor Roosevelt Institute in Colorado.



Benny (Yi) Yang, PhD

CSO, Biocytogen

Dr. Yang graduated from Fudan University with a Master's degree in Microbiology. He received his Ph.D. degree in Immunology from the University of Connecticut and completed his postdoctoral training at New York University School of Medicine in Dr. Dan Littman's research group. Then Dr. Yang was recruited to the Medical University of South Carolina (MUSC) as a tenure-track Assistant Professor in the Department of Microbiology and Immunology. In 2016, he joined Biocytogen as the Chief Scientific Officer, where he leads the Institute for Biologics. Dr. Yang has been instrumental in spearheading antibody drug discovery and has overseen the development of dozens of therapeutic antibody-based drugs, successfully advancing multiple projects to IND and clinical stages.




Zhiqiang An, PhD

Vice President of Drug
Discovery, University of Texas
Health Science Center

Dr. Zhiqiang An is a professor and the Robert A. Welch Distinguished University Chair in Chemistry, director of the Texas Therapeutics Institute, and vice president of drug discovery at the University of Texas Health Science Center at Houston. His laboratory focuses on antibody drug discovery. During the last 10 years, he has advanced more than 10 innovative antibody-based therapies to preclinical and clinical development for diseases ranging from acute myeloid leukemia, cancer bone metastasis, solid tumor, spinal cord injury, fibrosis, and COVID-19. Previously, he served as Chief Scientific Officer at Epitomics, Inc., and was Director of Biologics Research at Merck. Dr. An is an elected fellow of the Society for Industrial Microbiology and Biotechnology (SIMB), the American Academy of Microbiology (ASM), the American Association for the Advancement of Science (AAAS), and the National Academy of Inventors (NAI). He received the 2024 Scientific Achievement Award in Drug Discovery and Development from the American Society for Pharmacology and Experimental Therapeutics (ASPET). Dr. An received his Ph.D. from the University of Kentucky and his postdoctoral training at the University of Wisconsin-Madison.

SPONSORS




DIMA Highlights

Off-the-shelf Therapeutic Lead mAbs and Membrane Protein Nanodisc



Technology Platform & Products



Discovery of ADC&CAR-T Lead Molecules



No Upfront No Waiting No Risk

- Off-the-shelf Therapeutic lead mAbs
- Prevalidated B Cell Libraries
- Pre-clinical Validation Data Package available
- Custom ADC&CAR-T Projects

Prevalidated mAbs against Popular ADC/CAR-T Targets



Scan me to view the lead mAbs list

Synthetic Nanodisc-Full length Transmembrane Proteins

- 500+ targets in stock
- Wide coverage on **GPCRs**, **ion-channels**, etc.
- Comprehensive validation
- Custom production
- Applications in Cryo-EM, small molecule drug screening, etc




SDS-PAGE




cat. No.FLP100726,
24-pass Na⁺ ion channel

SEC-HPLC




Cat. No. FLP100048,
12-pass Cystine/glutamate transporter

ELISA



Cat. No. FLP100011,
7-pass GPCR

SPR



Cat. No. FLP120031,
7-pass GPCR



DIMA Biotechnology LLC

☎ 240-237-2678

✉ info@dimabio.com

🌐 www.dimabio.com



Your partner in recombinant proteins & enzymes

Bringing Quality, Speed, and Innovation to Your Research with 3000+
Made-in-House Catalog Proteins

Full-Length Multi-Pass Transmembrane Proteins


Displayed on Virus-like Particles (VLPs)



Features: Boosted immunogenicity, Biotinylation & Fluorescent Labeling, Difficult-to-express targets, Boosted immunogenicity, Detergent-free extraction nanodiscs

Applications: ELISA, SPR, BLI, Yeast Display, Immunization

Displayed on Copolymer Nanodiscs



Features: Detergent-free extraction, Solubilized proteins, Mammalian expression, Bioactivity verified, Biotinylation & fluorescent labeling

Applications: SPR, BLI, ELISA, Yeast Display

Example targets: GPRC5D, Claudin 6, CD20, Claudin 18.2 GPC3, CCR2b, SLC7A1, MRGPRX2, A2AR

MHC Monomers & Tetramers




Mammalian-expressed MHC-peptide complexes

Peptide-ready MHCs: Load your own peptide in-house with a quick and simple protocol

Features: Class I & Class II Alleles, Fluorescent Labeling, Biotinylation,

Gene Therapy Enzymes & Reagents



- AccuBase™ Cytosine Base Editor, GMP-Grade
- Cas9 Protein, GMP-Grade
- Cas12a, Research-Grade
- Non-specific Endonuclease, GMP-Grade
- AAV Titration ELISA Kits
- TelN Protelomerase

Custom Services

- Custom VLP & Nanodisc Proteins
- Custom MHC Molecules
- Soluble TCR Expression
- SPR Analysis Services
- Custom Protein Expression

Ask us for difficult-to-express targets!

Why choose KACTUS?

- Extensive Catalog: Over 3000 catalog products ready-to-ship
- Fast Delivery: Next-day shipping from Boston, MA
- Premium Quality: Verified bioactivity and purity
- Elite Customer Support: Responsive and informative scientific support



support@kactusbio.us

kactusbio.com



Sepax Technologies, Inc.

SPECIALIZED AND INNOVATIVE CHROMATOGRAPHY EXPERTS

Analytical, Preparative, Process-Scale Bioseparation Applications


HPLC Columns | Process Media | Services

Through innovative technologies and solution-based approaches, Sepax delivers products and services that build lasting relationships with customers. Whether you are conducting analytical research, in need of customized resins, or scale-up purification, we offer unmatched technical capabilities and expertise. Working in tandem with our technical team and our customers, Sepax offers highly individualized services to meet your specific requirements, achieving project goals in an efficient and cost-effective manner.


Sepax-Tech.com
Info@Sepax-Tech.com
1-877-SEPAX-US

LinkedIn.com/company/
sepax-technologies-inc

Newark, Delaware USA



FULL LIFE CYCLE SUPPORT OF ANALYTICAL AND BIOPROCESS CHROMATOGRAPHY



We help you discover life

HUGO-Ab™ Mouse Model


HUmanized GeNomic Ortholog for Antibody Development

Revolutionize Your Therapeutic Antibody Discovery with
our Breakthrough Fully Human Antibody Mouse Model

- Humanization of Immunoglobulin Variable Regions
- Robust Immune Response
- High-Affinity Fully Human Antibodies
- Rich Diversity of Fully Human Antibody Sequences
- Optimized for Antibody Drug Discovery



www.cyagen.com




BIOSYSTEMS
Acro

Where Protein and Innovation Advance Biomedicine

Core Product and Services

Built on Industry-Leading Technology Platforms
Offering Diverse Product Selections for Customers

- Recombinant Proteins
- Antibody
- Enzyme
- Residual Detection Kits
- Cell Lines
- Growth Factors
- Magnetic Beads
- GMP Grade Solutions
- Analytical Services
- Service
- Pathology
- Organoid Toolbox



Learn more about ACROBiosystems at:
www.acrobiosystems.com

BIO MICE INNOVATIVE MODELS TO ACCELERATE DRUG DISCOVERY

Bioctyogen is a global biotech company advancing antibody drug development through innovative technologies. Leveraging gene-editing expertise, it pioneered drug target knock-in humanized models and offers 3,000+ models via BioMice™, along with in vivo, ex vivo, and in vitro pharmacology and custom gene-editing services.

Bioctyogen drives fully human monoclonal antibody discovery and offers 400,000+ antibody sequences targeting 1,000 proteins through its RenBiologics™ sub-brand for global partnerships

PRODUCTS & SERVICES OVERVIEW

- Drug target humanized models
- Gene targeting services
- Preclinical pharmacology services



Antibody Discovery In A Day !

AI-powered, cloud-based AbFinderAI™ and customized cell analysis and sorting!



Hypercell® is a high - throughput cell analysis and sorting platform that enables researchers to analyze and sort cells that are secreting proteins of interest quickly and at an affordable price. Our platform meets today' s high throughput demands, combined with a high degree of automation to minimize operator input, creating more time for innovation and discovery.

E-mail: hello@bioelectronica.com

Web: www.bioelectronica.com



www.biointron.com

12+
Years of experience

2,000+
Companies served globally

100,000+
Antibodies delivered annually

Small-Scale Packages

For Antibody Production

RUSHMAB™

RushMab™-Gene
100 ug transcription grade expression plasmids
Production Timeline: 4 days

RushMab™-Super
1 mg equivalent, Expression plasmids
Production Timeline: 3 days

RushMab™-Mini
100 ug purified antibody, Expression plasmids
Delivery in 10 days

RushMab™-Standard
1 mg purified antibody, Expression plasmids
Delivery in 10 days

Bispecific Antibody Production

Any format can be expressed

2-3 Weeks Delivery From Sequences to BsAbs

High-Throughput
500+ molecules/batch

Customized Service
Personalized approach just for you

Fast Turnaround
As fast as 2 weeks



AbDrop™: FULLY HUMAN ANTIBODY DISCOVERY

High-throughput *Fully Human Antibody Discovery Platform*

Go from target to fully human antibody in just **3 months!**



info@biointron.com

+1 (732) 790 - 8340

Shanghai, China | New Jersey, US

Few firms have protected more innovative and valuable IP than Fish & Richardson

From our earliest days, Fish has represented pioneering life science innovators who disrupt industry norms and transform the process by which the industry brings lifesaving technologies to patients. Across our 15 offices in the U.S., Europe, and China, our team is composed of some of the world's most respected and sought-after life science IP professionals. When clients come to Fish to build an IP strategy, they know that we will leave no stone unturned when crafting creative and comprehensive solutions to maximize the value of their IP.

fr.com | [@FishRichardson](https://twitter.com/FishRichardson)

Atlanta | Austin | Boston | Chicago | Dallas | Delaware | Houston | Minneapolis | Munich
New York | Orange County | San Diego | Shenzhen | Silicon Valley | Washington, D.C.



TurboCHO™ **NEW** Expression Service

As Fast As **5** Business Days



MOLECULAR
BIOLOGY



PEPTIDE



PROTEIN



ANTIBODY



GENE
EDITING



IVT
RNA

ABOUT US

IntelliPro Group (IPG), established in 2009 in Silicon Valley, USA, is a leading provider of integrated HR solutions. IPG focuses on creating a global AI-driven talent platform, offering comprehensive HR services for enterprises expanding overseas, from recruitment to employment.

IntelliPro Bio, a division of IPG, specializes in tailored talent solutions, HR services, and consulting for the Life Sciences and Healthcare industries, including executive search, global expansion support, and investment and financing services.

MISSION
Committed to building a globally leading AI-driven platform for efficient talent matching and development.


VISION
Empowering global enterprises to thrive worldwide.

CORPORATE BUSINESS

 Talent Solutions Executive Search Staffing RPO	 HR Solutions EOR PEO HRO	 Consulting Solutions Global Expansion Financial Advisory Strategic Consulting
---	---	--



GLOBAL SERVICE COVERAGE



Prometheus Panta

High quality, multi-parameter stability characterizations to help you select the best biologics candidates



Built for stability characterization.

- Measure thermal and colloidal stability parameters in parallel
- Fully automatable via gRPC framework
- Label-free, in-solution measurements
- Minimal sample consumption



Learn more at nanotempertech.com/prometheus/



**Empowering Global
Biotherapeutic Innovation**

Nona Biosciences is a global biotechnology company providing antibody discovery, engineering, and development services from idea to IND. With integrated capabilities and proprietary technology platforms, Nona supports the rapid advancement of antibody-based therapeutics through a streamlined, full-service approach.

Our foundational Harbour Mice® platforms produce fully human H2L2 and heavy chain-only (HCAb) antibodies — enabling highly developable, low-immunogenicity candidates without the need for humanization. These clinically validated platforms, combined with advanced engineering and developability assessment, help streamline the path from hit to IND. Building on this foundation, our Modalities-on-Demand™ offering applies the HCAb format to power a range of next-generation modalities, including bi- & multispecific antibodies (e.g., T cell engagers), ADCs, cell therapies, and mRNA therapeutics.

Nona has supported over 300 programs globally, including 19+ in the IND or clinical stage, and offers flexible collaboration models tailored to each partner's goals.

[Learn More](#)



Modalities-on-Demand™

Bi & Multispecific Antibodies



ADCs



Cell Therapies



mRNA Therapeutics



YUROGEN
A subsidiary of ABclonal

Antibodies Empowered by SAb™ Single B-cell Tech

Our Services:

- Antibody Discovery ✓
- Antibody Engineering ✓
- Protein Expression ✓

NEW SPR
Analysis

10+
Years

100+
Clients served

1,000+
Projects completed

10,000+
Custom mAbs delivered

www.yurogen.com | customer@yurogen.com



Biological Drug R&D Ask Sanyou Bio

Differentiated CRO

Integrated CDO

Innovative CPO

Characteristic CRS

Sanyou Biopharmaceuticals Co., Ltd. is a high-tech biopharmaceutical company with the vision of "improving the quality of human life through innovative biologics" and the mission of "to make the R&D easy for innovative biologics". The company is headquartered in Shanghai, China, with subsidiaries in the United States, Europe, and other regions. It has over 20,000 square meters of R&D and GMP facilities that are currently in operation or under planning.

The company has established a world-leading preclinical intelligent and integrated R&D platform for innovative biologics, centered around an innovative platform of super-trillion antibody library. This platform accelerates the development of innovative biologics across four dimensions: new drug discovery, preclinical research, AI-assisted drug development, and frontier scientific research.

Sanyou provides a comprehensive "4C" business model for innovative biologics, combining differentiated CRO, integrated CDO, collaborative CPO, and specialized CRS. The company has built a global marketing network and established business with over 1,200 pharmaceutical and biotech companies worldwide. It has completed more than 1,200 new drug discovery and development service projects, with over 50 collaborative R&D projects, including 9 that have obtained IND approval. The company has also developed thousands of RUO reagents. Sanyou has also received a number of nationwide and Shanghai recognitions and awards.

Sanyou Biopharmaceuticals Co., Ltd.

www.sanyoubio.com +8621 3368 1627 service@sanyoubio.com

About Us

Crystal Bio Solutions, a wholly owned subsidiary of Crystal Pharmatech Inc., consists of **Biologics CMC Analytical Lab & Bioanalytical and Biomarker Lab** with 3 sites across USA.

- The expertise spans a broad range of therapeutic modalities including antibody, bi/multi-specifics, protein, ADC, CGT, mRNA, LNP, nucleotide, vaccine and virus.
- Crystal Bio Solutions is committed to being your trusted partner and providing the highest quality deliverables through sound science and operational excellence.

Biologics CMC Analytical Services

- High-resolution Mass Spectrometry
- Product Quality Analysis
- Process Impurity Analysis
- Developability Assessment, Pre-formulation Study for IND Enabling
- Bio-analytics
- Additional Capabilities

Bioanalysis and Biomarker Services

- Immunoassays
- LCMS
- Cell-based Assays
- Flow Cytometry
- ELISpot Assays
- Molecular Biology



Crystal Bio Solutions
A Member of Crystal Pharmatech

www.crystalpharmatech.com +1-609-604-8303 BD_Global@crystalpharmatech.com

AntibodyTherapeutics

ABOUT THE JOURNAL

Antibody Therapeutics is the official journal of Chinese Antibody Society, published by Oxford University Press. As an international peer-reviewed open access journal, *Antibody Therapeutics* provides a forum for the publication of the latest advances and challenges in the discovery, research, development, manufacturing, and methodology of therapeutic antibodies for the global scientific community. *Antibody Therapeutics* is indexed by ESCI, PubMed and Scopus with 2023 CiteScore 8.7.



Editor-in-Chief: Dr. Mitchell Ho
Senior Investigator, Deputy Chief, Laboratory of Molecular Biology, National Cancer Institute (NCI), National Institutes of Health (NIH), USA



Deputy Editor-in-Chief: Dr. Zhiqiang An
Professor and Robert A. Welch Distinguished University Chair in Chemistry, UTHealth Houston, USA

VISIT academic.oup.com/abt

to learn more or submit your manuscript


CONTACT abt.editorialoffice@publishingsolutions.net
for submission questions

CALL FOR PAPER

THE OFFICIAL JOURNAL OF THE CHINESE ANTIBODY SOCIETY

AntibodyTherapeutics


• Original Research Articles • Reviews • Methods • News and views • Meeting reports and interviews



Submit by 31 Dec 2025, save 50% on Article Processing Charges

Recent Special Collections

1. Cell Therapies and Cell Engagers against Cancer
2. Formulation of Antibody-Based Therapeutics
3. Antibody-Drug Conjugates for Cancer Treatment
4. Bispecific Antibody CMC





The Chinese Antibody Society
955 Massachusetts Ave #276
Cambridge, MA 02139, USA

Email: management@chineseantibody.org

Website: www.chineseantibody.org

LinkedIn: www.linkedin.com/company/chineseantibodysociety/

Journal: academic.oup.com/abt

Facebook: www.facebook.com/ChineseAntibody/